Literature DB >> 7683890

Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharides extracted by new micromethods from all serotypes of Pseudomonas aeruginosa.

A Fomsgaard1, G H Shand, M A Freudenberg, C Galanos, R S Conrad, G Kronborg, N Høiby.   

Abstract

Micromethods were developed to extract lipopolysaccharide (LPS, endotoxin) from single bacterial colonies of the 20 recognized Pseudomonas aeruginosa type strains. The appearance of these LPSs in polyacrylamide gel electrophoresis (PAGE) and their reactivity with serum of cystic fibrosis (CF) patients chronically infected with P. aeruginosa was studied. Silver staining of LPS after PAGE showed that 13 of the P. aeruginosa LPSs had high numbers of O-repeating units arranged in 1-4 clusters of banding. Low-molecular-weight LPS fractions were more prominent in six of the serotype strains, of which O:7 and O:14 appeared semi-rough. Corresponding immunoblots using the CF sera showed LPS patterns very similar to the silver-stained appearance, indicating an immune reaction to all P. aeruginosa LPS including that from the newly discovered O:18, O:19 and O:20. This was unexpected since only a few serotype strains (mostly O:3, O:6 and O:9) had been isolated from the patients. Absorption experiments using purified and chemically defined P. aeruginosa rough LPS and smooth LPS suggested these immune reactions were due to antibodies cross-reactive to core/lipid A as well as to lower molecular weight O-polysaccharides or "A-bands". However, in some cases O:3, O:6, and O:9 LPSs were also found to contain additional distinct O-epitopes. Immune recognition of various polyagglutinable P. aeruginosa LPSs seemed also to be caused by cross-reactive antibodies. The described microextraction methods, followed by PAGE and silver staining or immunoblotting, are easy and convenient techniques with which to study antibodies against LPS epitopes and to screen for LPS phenotypic appearance using only a few bacterial colonies from larger numbers of Gram-negative bacterial strains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683890     DOI: 10.1111/j.1699-0463.1993.tb00088.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  Amoxicillin treatment of experimental acute otitis media caused by Haemophilus influenzae with non-beta-lactamase-mediated resistance to beta-lactams: aspects of virulence and treatment.

Authors:  A Melhus; H Janson; E Westman; A Hermansson; A Forsgren; K Prellner
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

3.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

4.  Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori.

Authors:  H K Johansen; A Nørgaard; L P Andersen; P Jensen; H Nielsen; N Høiby
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

5.  Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model.

Authors:  H Janson; A Melhus; A Hermansson; A Forsgren
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

Review 6.  Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Victoria L Campodónico; Mihaela Gadjeva; Catherine Paradis-Bleau; Ahmet Uluer; Gerald B Pier
Journal:  Trends Mol Med       Date:  2008-02-11       Impact factor: 11.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.